Haemonetics (NYSE:HAE) Sets New 12-Month High at $96.17

Haemonetics Co. (NYSE:HAE)’s stock price reached a new 52-week high on Monday . The company traded as high as $96.17 and last traded at $96.15, with a volume of 28001 shares traded. The stock had previously closed at $94.40.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Barrington Research reaffirmed an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

Haemonetics Trading Up 1.0 %

The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The stock has a market capitalization of $4.84 billion, a P/E ratio of 38.37, a P/E/G ratio of 2.23 and a beta of 0.34. The firm’s 50 day moving average price is $82.36 and its 200 day moving average price is $82.66.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. During the same quarter in the prior year, the company posted $0.85 EPS. Haemonetics’s quarterly revenue was up 10.1% compared to the same quarter last year. As a group, equities research analysts expect that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new position in Haemonetics during the fourth quarter valued at $28,591,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Haemonetics by 132.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock valued at $42,930,000 after purchasing an additional 286,897 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Haemonetics by 27.2% in the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock worth $60,888,000 after purchasing an additional 152,098 shares in the last quarter. Victory Capital Management Inc. increased its position in Haemonetics by 50.0% during the 3rd quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock valued at $32,007,000 after buying an additional 119,072 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. purchased a new position in Haemonetics during the third quarter valued at $9,952,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.